- Novel approach to treat neurodegenerative diseases by targeting fibrin-driven neuroinflammation was well-tolerated among healthy volunteers, with a clean hematological profile - - Half-life supports once-monthly dosing - - Data to be presented at AAIC 25 - April 29, 2025 Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced positive results from a Phase 1a trial assessing

An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safety These findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 April 29, 2025 -- Affimed N

April 28, 2025 New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of Medicine Data presented included an objective response rate (ORR) of 71%, with 7% of patients achieving complete responses (CR), and a 96% disease control rate (DCR) Previously unreported results, including median duration of response (DoR) of 14.1 months and median progression-free survival (PFS) of 12.4 months, indicate the potential for zongertinib t

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 202

In 2024, the field of cancer therapeutics has witnessed remarkable progress in targeting Claudin 18.2 (CLDN18.2). As a protein highly expressed in several malignancies—particularly gastrointestinal cancers such as gastric and pancreatic cancer—CLDN18.2 has emerged as a highly promising therapeutic target. Antibody-drug conjugates (ADCs) developed against this target, including Zolbetuximab, IBI-343, LM-302, and SHR-A1904, have shown encouraging preclinical and clinical results. These innovations

Johnson & Johnson, the 138-year-old global healthcare giant, with its iconic baby powder becoming a household staple across generations. However, beginning in the 1990s, the company was swept into a mounting legal crisis centered on allegations that its talc-based products caused cancer—a controversy that would eventually grow into one of the largest product liability litigations in U.S. history. As of 2025, over 38,000 plaintiffs worldwide have filed lawsuits, with cumulative claims exceed

Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimburse

ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025 April 23, 2025 – ImCheck Therapeutics announced today an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2025, taking place from May 30 to June 3, in Chicago, Illinois, USA. The presentation will focus on results from its ongoing open-label, randomized Phase I/II study EVICTION, including updated efficacy, safety and dose-selection dat

– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – April 23, 2025 -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at

April 23, 2025 -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company’s ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual